Pharmacists in both community and hospital settings are well-positioned to swiftly detect substandard and falsified (SF) medical products in supply chains, report them to the authorities, and educate and advise affected patients, FIP told the World Health Organization (WHO) Executive Board in Geneva, Switzerland, today.

Speaking on behalf of FIP during the agenda item on SF, Tjaša Škerl Rifelj, from the International Pharmaceutical Students' Federation, welcomed the WHO Member State mechanism’s efforts to address SF medical products and facilitate collaboration among stakeholders. In the statement, FIP highlighted its collaboration with WHO as proof of the critical role pharmacists play in detecting and reporting SF products, underscoring the importance of their involvement in tackling this issue, as well as the positive outcomes resulting from this partnership.

During the Executive Board meeting this week, FIP is also taking part in joint statements on the health and care workforce, climate change, and health emergencies with the World Health Professions Alliance (WHPA) and members of the Health Stakeholder Network (HSN). Access them here.